Inovio Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inovio Pharmaceuticals (INO).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

2S.Buy

4Buy

2Hold

Consensus RatingMarket Outperform# Analysts8Avg. Consensus PT$14Upside to Avg. PT+1437.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Jefferies	Roger Song	Upgrade	Hold→Buy	$2→$3
Aug 3, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$6→$4
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$3→$3
Nov 14, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$5→$6
Aug 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$3
Jul 9, 2025	Piper Sandler	Edward Tenthoff	Initiate	Overweight	$5
May 14, 2025	RBC Capital	Gregory Renza	Maintained	Sector Perform	$5
May 14, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$15→$13
Mar 19, 2025	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$6→$5
Mar 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$3
Mar 14, 2025	Citizens Capital Markets	Roy Buchanan	Maintained	Market Outperform	$18
Jan 13, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$5→$3
Jan 10, 2025	JMP Securities	Roy Buchanan	Maintained	Market Outperform	$18
Nov 18, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$12→$5
Nov 18, 2024	Oppenheimer	Jay Olson	PT Cut	Outperform	$33→$15
Nov 15, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$7→$6
Oct 4, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$8→$7
Aug 12, 2024	Oppenheimer	Jay Olson	PT Cut	Outperform	$40→$33
Aug 9, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$11→$8
Jul 15, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$15

Analyst Ratings News

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $3 price target.

Benzinga Newsdesk

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Inovio Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Inovio Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

Inovio Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Inovio Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PROPiper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PROHC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PROPiper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PROHC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target